Description: IFRS 17 will be effective as of 1 Jan 2023 and provide opportunities as well as challenges to both Direct Writers and Reinsurers across the insurance industry. If the new framework is not fully understood, an implementation can elevate the risk of problems in financial reporting, product development, investment management and more. The transition to IFRS provides an opportunity for companies to optimize the financial position of the enterprise by implementing mitigating strategies to reduce the risks and challenges that IFRS brings to the table.

Description: 2021 Life Meeting - Session 7F: A New Frontier for Reinsurance Accounting - LDTI vs. IFRS 17 9.1.21 Recording

Description: Life insurance has no shortage of issues and innovations impacting the day-to-day life of products, a product actuary and the life insurance process. Listen to a group of experts discuss the key topics faced when issuing and managing life products, including innovations, regulations, growth, opportunity and cautions pertaining to Term, whole life, and UL products. By attending the session, you will: Be able to identify trends in life products and processes, avoid pitfalls of product development through increased awareness of innovations and issues, and identify key developments that could impact life products.

Description: Session 9A: Variable Annuity Inforce Transactions: Trend and Considerations The VA M&A market has been very active in recent years with multiple transactions announced last year alone. Explore the driving forces behind this trend and discuss key considerations for VA inforce transactions.Take a deep dive into key areas of transaction due diligence process. By attending the session, you will: Be able to learn the key drivers of recent VA inforce transactions and the key considerations in the transaction due diligence.

Description: Reinsurance has become more frequently used in the annuity market along with large M&A transactions over the past few years. Discuss the market forces and the impact to the product development and pricing. By attending the session, you will: Understand the benefits of reinsuring annuities and the types of reinsurance used for annuities.

Description: LDTI requires that reinsurance recoverables be recognized in a manner consistent with the liabilities of underlying direct contracts. Consider implications of multiple ceded reinsurance contracts (e.g., coinsurance and YRT on the same business) and how this impacts the calculation of the net premium ratio (NPR) and other related approximations. Explore different options when only some of the policies within a cohort are reinsured. Multiple interpretations of the components of the NPR formula exist. Two main approaches will be presented-standalone and integrated approach. Other considerations to be discussed include implications of closed-block reinsurance transactions at transition and subsequent to transition, contra-DAC, market risk benefits. Finally, explore the short-duration YRT approximation (1/2 Cx) compared to the long-duration calculation.

Description: As the size of the life reinsurance market in Bermuda has grown to over half a trillion dollars at the end of 2021, more and more actuaries are getting involved with this 21 square mile North Atlantic island in one way or the other. Come explore a fundamental understanding of the Bermuda solvency framework and an overview of its upcoming changes.

Description: Join us for the Recent Trends in the Competitive Landscape webcast where you'll find an exploration of the how the insurance industry is rapidly evolving. Discover various structures and reinsurance strategies that will improve a competitive position in the insurance landscape. Come learn about the latest structures used by insurers in the market, which will focus on asset strategies that create a growing segment of the Life and Annuity insurer landscape. Indicate the key components of asset strategies that result in significant changes to the insurance investment landscape.

Description: With Chapter 20 of the National Association of Insurance Commissioners Valuation Manual (VM-20), the expansion of accelerated underwriting programs and digital distribution, new accounting standards under GAAP long-duration targeted improvements (LDTI) and International Financial Reporting Standard (IFRS) 17, along with a changing interest rate environment, companies may be looking for efficient reinsurance solutions to help address these ever changing and varied challenges. Hear highlights on how reinsurance can be utilized to address the challenges associated with managing new business strain and product competitiveness, earnings and risk management, and capital allocation efficiency. At the conclusion of the session, you will understand the various challenges being faced by direct writing companies today and where reinsurance can be leveraged to improve the returns and competitiveness of product offerings, provide flexibility in capital and tax planning, as well as balancing risk appetite and underwriting profit retention.

Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.